slot machine big win
ON Semiconductor Corporation ( NASDAQ: ON ) Nasdaq Investor Conference December 10, 2024 11:00 AM ET Company Participants Hassane El-Khoury - CEO Thad Trent - CFO Conference Call Participants Joe Moore - Morgan Stanley Joe Moore Great. Thank you, everybody. I'm Joe Moore back again. Very happy to have with us the management team of ON Semi, Hassane El-Khoury, CEO; and Thad Trent, CFO. Question-and-Answer Session Q - Joe Moore So maybe if go off-script breaking news today that you've acquired the Universal Silicon Carbide business from Qorvo. Can you talk a little bit about that? What benefits do you guys see from that? Hassane El-Khoury Sure. So if you think about the strategic rationale, of course, we're a power semiconductor provider, including silicon carbide and wide bandgap, and we've always said that the competitive advantage that we have is the ability to give customers a solution to stay look for their specific needs and or optimized. So how does that -- the acquisition of the silicon carbide JFET business fit into this overall strategy and more appropriately, how does it fit the customer need. With the emergence of AI, the AI trajectory from a power perspective is increasing every generation. And now the AI server going from 40-kilowatt to, call it, hundreds of kilowatts, as that transition happens, you start to need more of wide bandgap technology devices rather than just a silicon from an efficiency perspective, but also from a cost and area. Because a rack doesn't get any different. The size of a rack, the XY and height are almost spec-ed. So therefore, real estate is important. So you need a more compact power solution that is able to provide the efficiency when you deploy at scale. That's what the silicon carbide JFET does for us. It's a smaller die. It's a higher efficiency, higher frequency product than this regular -- even silicon carbide. And with our ability to, over time, bring that in, it gives us that also a competitive advantage fromLSU outlasts UCF 109-102 in triple-OT affair
LANDOVER, Md. (AP) — Jimmy Carter was honored with a moment of silence before the Atlanta Falcons’ game at the Washington Commanders on Sunday night, hours after the 39th president of the United States died at the age of 100 in Plains, Georgia. Beyond being a Georgia native who led the country from the White House less than 8 miles (12 kilometers) away during his time in office from 1977-81, Carter was the first president to host the NFL's Super Bowl champions there when he welcomed the Pittsburgh Steelers in 1980. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get our free email newsletters — latest headlines and e-edition notifications.
SAN DIEGO , Dec. 10, 2024 /PRNewswire/ -- Robbins LLP reminds investors of the class action filed on behalf of all persons and entities that purchased or otherwise acquired Humacyte, Inc. (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024 . Humacyte and its consolidated subsidiaries develop and manufacture off-the-shelf, implantable, and bioengineered human tissues. For more information, submit a form , email attorney Aaron Dumas, Jr. , or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Humacyte, Inc (HUMA) Misled Investors Regarding its Manufacturing Practices According to the complaint, Humacyte is currently engaged in engineering and manufacturing Acellular Tissue Engineered Vessel ("ATEV"), also known as "Human Acellular Vessel," which is a lab-grown blood vessel implant that can act as a replacement for an injured or damaged blood vessel. On August 9, 2024 , Humacyte issued a press release announcing that the FDA "will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication." The press release disclosed in part, that, "[d]uring the course of the BLA review, the FDA has conducted inspections of our manufacturing facilities and clinical sites and has actively engaged with us in multiple discussions regarding our BLA filing[.]" On this news, the Company's stock price declined $1.29 , or 16.4%, to close at $6.62 per share on August 12, 2024 . The complaint further alleges that on October 17, 2024 , the FDA released a Form 483 concerning Humacyte's Durham, North Carolina facility, which revealed violations, including "no microbial quality assurance," "no microbial testing," and inadequate "quality oversight." On this news, the Company's stock price declined $0.95 , or 16.35%, to close at $4.86 per share on October 17, 2024 . Plaintiff alleges that during the class period, defendants failed to disclose to investors: (1) that the Company's Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) that the FDA's review of the BLA would be delayed while Humacyte remediated these deficiencies; and (3) that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma. What Now : You may be eligible to participate in the class action against Humacyte, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by January 17, 2025 . A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP : Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Humacyte, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. View original content to download multimedia: https://www.prnewswire.com/news-releases/huma-stockholders-with-large-losses-should-contact-shareholder-rights-law-firm-robbins-llp-for-information-about-the-humacyte-inc-class-action-302328207.html SOURCE Robbins LLP
Hezbollah fires about 250 rockets and other projectiles into Israel in heaviest barrage in weeksChina investigates defence minister for corruption: report
Drill Presses Market Driven by Demand for Immersive Technologies Across IndustriesJimmy Carter, the United States’ longest-lived president, was never afraid to speak his mind. Forthright and fearless, the Nobel Prize winner took potshots at former British prime minister Tony Blair and ex-US president George W Bush, among others. His death came after repeated bouts of illness in which images of the increasingly frail former president failed to erase memories of his fierce spirit. Democrat James Earl “Jimmy” Carter Jr swept to power in 1977 with his Trust Me campaign helping to beat Republican president Gerald Ford. Serving as the 39th US president from 1977 to 1981, he sought to make government “competent and compassionate” but was ousted by the unstoppable Hollywood appeal of a certain Ronald Reagan. A skilled sportsman, Mr Carter left his home of Plains, Georgia, to join the US Navy, returning later to run his family’s peanut business. A stint in the Georgia senate lit the touchpaper on his political career and he rose to the top of the Democratic movement. But he will also be remembered for a bizarre encounter with a deeply disgruntled opponent. The president was enjoying a relaxing fishing trip near his home town in 1979 when his craft was attacked by a furious swamp rabbit which reportedly swam up to the boat hissing wildly. The press had a field day, with one paper bearing the headline President Attacked By Rabbit. Away from encounters with belligerent bunnies, Mr Carter’s willingness to address politically uncomfortable topics did not diminish with age. He recently said that he would be willing to travel to North Korea for peace talks on behalf of US President Donald Trump. He also famously mounted a ferocious and personal attack on Tony Blair over the Iraq war, weeks before the prime minister left office in June 2007. Mr Carter, who had already denounced George W Bush’s presidency as “the worst in history”, used an interview on BBC radio to condemn Mr Blair for his tight relations with Mr Bush, particularly concerning the Iraq War. Asked how he would characterise Mr Blair’s relationship with Mr Bush, Mr Carter replied: “Abominable. Loyal, blind, apparently subservient. “I think that the almost undeviating support by Great Britain for the ill-advised policies of President Bush in Iraq have been a major tragedy for the world.” Mr Carter was also voluble over the Rhodesia crisis, which was about to end during his presidency. His support for Robert Mugabe at the time generated widespread criticism. He was said to have ignored the warnings of many prominent Zimbabweans, black and white, about what sort of leader Mugabe would be. This was seen by Mr Carter’s critics as “deserving a prominent place among the outrages of the Carter years”. Mr Carter has since said he and his administration had spent more effort and worry on Rhodesia than on the Middle East. He admitted he had supported two revolutionaries in Mugabe and Joshua Nkomo, and with hindsight said later that Mugabe had been “a good leader gone bad”, having at first been “a very enlightened president”. One US commentator wrote: “History will not look kindly on those in the West who insisted on bringing the avowed Marxist Mugabe into the government. “In particular, the Jimmy Carter foreign policy... bears some responsibility for the fate of a small African country with scant connection to American national interests.” In recent years Mr Carter developed a reputation as an international peace negotiator. He won the Nobel Peace Prize in 2002 for his commitment to finding peaceful solutions to international conflicts, his work with human rights and democracy initiatives, and his promotion of economic and social programmes. Mr Carter was dispatched to North Korea in August 2008 to secure the release of US citizen Aijalon Mahli Gomes, who had been sentenced to eight years of hard labour after being found guilty of illegally entering North Korea. He successfully secured the release of Mr Gomes. In 2010 he returned to the White House to greet President Barack Obama and discuss international affairs amid rising tensions on the Korean peninsula. Proving politics runs in the family, in 2013 his grandson Jason, a state senator, announced his bid to become governor in Georgia, where his famous grandfather governed before becoming president. He eventually lost to incumbent Republican Nathan Deal. Fears that Mr Carter’s health was deteriorating were sparked in 2015 when he cut short an election observation visit in Guyana because he was “not feeling well”. It would have been Mr Carter’s 39th trip to personally observe an international election. Three months later, on August 12, he revealed he had cancer which had been diagnosed after he underwent surgery to remove a small mass in his liver. Mr Obama was among the well-wishers hoping for Mr Carter’s full recovery after it was confirmed the cancer had spread widely. Melanoma had been found in his brain and liver, and Mr Carter underwent immunotherapy and radiation therapy, before announcing in March the following year that he no longer needed any treatment. In 2017, Mr Carter was taken to hospital as a precaution, after he became dehydrated at a home-building project in Canada. He was admitted to hospital on multiple occasions in 2019 having had a series of falls, suffering a brain bleed and a broken pelvis, as well as a stint to be treated for a urinary tract infection. Mr Carter spent much of the coronavirus pandemic largely at his home in Georgia, and did not attend Joe Biden’s presidential inauguration in 2021, but extended his “best wishes”. Former first lady Rosalynn Carter, the closest adviser to Mr Carter during his term as US president, died in November 2023. She had been living with dementia and suffering many months of declining health. “Rosalynn was my equal partner in everything I ever accomplished,” Mr Carter said in a statement following her death. “She gave me wise guidance and encouragement when I needed it. As long as Rosalynn was in the world, I always knew somebody loved and supported me.”